Skip to main content

Table 1 Selected clinical efficacy on selected third generation EGFR TKIs in clinical development

From: Third generation EGFR TKIs: current data and future directions

Third Generation EGFR TKI Status of development Trial Dose n ORR PFS (mth)
(95% CI)
Adverse events
(selected all grade)
Osimertinib
(AZD9291)
Approved for T790 M mutation post EGFR TKI AURA 3
NCT01802632
80 mg daily 279 71%
(65–76%)
10.1 (8.3–12.3) Diarrhea (41%); rash (34%), paronychia (22%); pneumonitis (4%)
Olmutinib Developing in Korea NCT01588145 800 mg daily 76 56% 7.0
(5.5–8.3)
Diarrhea (55%), rash (39%), nauseas (38%).
Nazartinib (EGF816) Phase I/II NCT02108964 75-350 mg QD 132 44% 9.2
(9.0-NE)
Diarrhea (40%), maculopapular rash (39%), pruritus (32%), stomatitis (23%), and fatigue (21%).
Avitinib (AC0010) Phase I/II
(phase II AEGIS-1 trial had started)
NCT02330367 50-350 mg BID
150-300 mg cohort
136
95
44% a
51%
NA Diarrhea (38%) and rash (24%)
  1. EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, ORR objective response rate, PFS progression free survival, n number of participant, NE not evaluable, NA not available
  2. a including unconfirmed responses